Omniox's Series B Round

Omniox raised a round of funding on June 18, 2014.

Omniox is an IND-stage biotherapeutics company developing OMX as a broad-acting cancer immunotherapy. OMX is engineered to deliver oxygen safely into hypoxic, immunosuppressive tumor microenvironments…

Articles about Omniox's Series B Round: